News

AstraZeneca announced that it has entered into a licensing agreement with Ironwood Pharmaceuticals for the exclusive US rights to Zurampic® (lesinurad). Zurampic was approved by the US Food and Drug Administration (FDA) in December 2015, in combination with a...

Chugai Pharma and TWO CELLS Co Ltd announced that on April 25, 2016, both companies concluded a licensing agreement regarding gMSC®1, a regenerative cellular medicine for chondrogenesis in the knee, created by TWO CELLS.  Under this...

Amgen announced plans to participate in the World Medical Innovation Forum™ on cancer held April 25-27, 2016, in Boston. The World Medical Innovation Forum is a global gathering of senior corporate, investor and academic leaders. The forum was established...

Launched on 28 October 2015 , the European Commission’s new strategy ‘A Single Market Strategy for Europe – Analysis and Evidence’ proposes a manufacturing waiver during the SPC period to allow the EU generic and biosimilar medicines industries...

Bayer AG and its development partner Janssen Pharmaceuticals, Inc announced results from a new real-world study, REVISIT-US.  In REVISIT-US reduced rates of ischemic stroke accompanied by reduced rates of intracranial haemorrhage (ICH) were seen with Xarelto®...

Genentech, a member of the Roche group announced that new data from three Phase III studies of the investigational medicine OCREVUS™ (ocrelizumab) will be presented during the 68th American Academy of Neurology (AAN) annual meeting from April 15-21...

Sanofi announced a €300 million investment to expand its site in Geel, Belgium. The investment furthers Sanofi’s commitment to driving the future of biologics by expanding manufacturing and commercial capabilities in order to ensure quality, capacity, and scale. ...